Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy.

Wang L, Liu JQ, Talebian F, El-Omrani HY, Khattabi M, Yu L, Bai XF.

Eur J Immunol. 2010 Sep;40(9):2569-79. doi: 10.1002/eji.201040472.

2.

IL-10 contributes to the suppressive function of tumour-associated myeloid cells and enhances myeloid cell accumulation in tumours.

Wang LX, Talebian F, Liu JQ, Khattabi M, Yu L, Bai XF.

Scand J Immunol. 2012 Mar;75(3):273-81. doi: 10.1111/j.1365-3083.2011.02662.x.

3.

The role of CD200-CD200R in tumor immune evasion.

Liao KL, Bai XF, Friedman A.

J Theor Biol. 2013 Jul 7;328:65-76. doi: 10.1016/j.jtbi.2013.03.017. Epub 2013 Mar 28.

PMID:
23541619
4.

Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.

Bai XF, Liu J, Li O, Zheng P, Liu Y.

J Clin Invest. 2003 May;111(10):1487-96.

5.

Effect of CD200 and CD200R1 expression within tissue grafts on increased graft survival in allogeneic recipients.

Yu K, Chen Z, Gorczynski R.

Immunol Lett. 2013 Jan;149(1-2):1-8. doi: 10.1016/j.imlet.2012.11.004. Epub 2012 Nov 21.

PMID:
23178470
6.

Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions.

Talebian F, Liu JQ, Liu Z, Khattabi M, He Y, Ganju R, Bai XF.

PLoS One. 2012;7(2):e31442. doi: 10.1371/journal.pone.0031442. Epub 2012 Feb 3.

7.

Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response.

Erin N, Podnos A, Tanriover G, Duymuş Ö, Cote E, Khatri I, Gorczynski RM.

Oncogene. 2015 Jul;34(29):3860-70. doi: 10.1038/onc.2014.317. Epub 2014 Sep 29.

PMID:
25263452
8.

Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs.

Liu JQ, Joshi PS, Wang C, El-Omrani HY, Xiao Y, Liu X, Hagan JP, Liu CG, Wu LC, Bai XF.

J Immunol. 2010 May 15;184(10):5435-43. doi: 10.4049/jimmunol.0903322. Epub 2010 Apr 19.

9.

Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.

Cayeux S, Richter G, Becker C, Beck C, Aicher A, Pezzutto A, Dörken B, Blankenstein T.

Eur J Immunol. 1997 Jul;27(7):1657-62.

PMID:
9247574
10.

Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.

Xie Y, Bai O, Zhang H, Li W, Xiang J.

Cancer Biother Radiopharm. 2010 Feb;25(1):21-8. doi: 10.1089/cbr.2009.0714.

PMID:
20187793
11.

A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.

Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP, Liotta LA, Berzofsky JA.

J Immunol. 1999 Jul 1;163(1):184-93.

13.
14.

Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis.

Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, Basu S, Feng Y, Bai XF.

J Immunol. 2013 Mar 1;190(5):2415-23. doi: 10.4049/jimmunol.1202535. Epub 2013 Jan 23.

15.
16.

Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte.

Tahara H, Fujio K, Araki Y, Setoguchi K, Misaki Y, Kitamura T, Yamamoto K.

J Immunol. 2003 Aug 15;171(4):2154-60.

17.
18.
20.

Intramuscular electroporation of a P1A-encoding plasmid vaccine delays P815 mastocytoma growth.

Vandermeulen G, Uyttenhove C, De Plaen E, Van den Eynde BJ, Préat V.

Bioelectrochemistry. 2014 Dec;100:112-8. doi: 10.1016/j.bioelechem.2013.11.002. Epub 2013 Dec 1.

PMID:
24342164

Supplemental Content

Support Center